India, China hold strategic dialogue

February 22, 2017

Beijing, Feb 22: China and India today held their upgraded strategic dialogue to shore up bilateral ties amid hectic parleys to resolve differences over Beijing's reluctance to support India's NSG bid as well as a UN ban on JeM chief Masood Azhar. Just before the dialogue, Foreign Secretary S Jaishankar held talks with Chinese Foreign Minister Wang Yi. Welcoming Jaishankar, co-chair of the dialogue, Wang said China and India are two major developing countries and emerging markets besides important nations in the world.

top

"We have to have frequent meetings," he said, referring to high-level talks held by officials from both sides on critical issues before today's dialogue. The official-level meetings made very good foundation for the "successful strategic dialogue", he said, adding that the Chinese side attaches importance to "this reconstituted dialogue". "I am certain by raising the level of this strategic dialogue the two sides will be able to enhance their strategic communication, reduce misunderstanding and build more trust and deepen our strategic cooperation," Wang said.

"This way we can better tap into the potential of our bilateral relations and live up to our responsibilities" for the regional stability. In his response, Jaishankar said, "This is the first time that the restructured strategic dialogue is taking place". "This shows that our relationship today has gone well beyond bilateral manifestations," he said.

Stating that the two countries are members of G20, Shanghai Cooperation Organisation (SCO), BRICS and the East Asia Summit, he said this will "allow us to find more common ground on more issues". Later, Jaishankar along with China's Executive Vice Foreign Minister Zhang Yesui held the strategic dialogue.

In his opening remarks at the dialogue, Jaishankar said, "We have truly transcended the bilateral dimension of our relations. What happens between India and China has both great global and regional significance.

"Our assessment coming in is that our bilateral relations have really acquired a very steady momentum over many years. Our leadership-level meetings have been taking place regularly and our economic engagement is growing. We are seeing cooperation on many international issues and our border areas have maintained peace and tranquility," he said.

"Overall the closer development partnership has been unfolding," he said. Apparently referring to differences, Jaishankar said, "there are natural issues which neighbours have" and it is the responsibility of both the countries to address them. Zhang said "I expect that we discuss the full range of issues that are important to our countries".

Several top officials from both sides, including those in-charge of nuclear disarmament issues, were present at the talks indicating that both sides will be discussing India's entry into the Nuclear Suppliers Group (NSG) besides other issues.

The talks were being held in the backdrop of vocal differences between the two countries on a host of issues including India's concern over the USD 46 billion China-Pakistan Economic Corridor (CPEC), Beijing's reluctance to back India's application to join the NSG and the UN ban on Azhar.

The strategic dialogue was upgraded during Chinese Foreign Minister Yi's visit to New Delhi last year. China has deputed Zhang, also the head of the influential Communist Party of China (CPC) committee of the Chinese Foreign Ministry to co-chair the talks.

Ahead of today's talks Jaishankar, who formerly worked as India's Ambassador to China, met China's top diplomat Yang Jiechi yesterday and held talks with him on the critical issues bedevilling the bilateral ties. During their talks, both Yang and Jaishankar expressed strong commitment to develop positive relations despite differences.

Yang, who is the State Councillor and Beijing's Special Representative for border talks between India and China, had said despite differences, relations between the two sides had a positive growth last year.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 10,2020

Paris, Apr 10: French pharma major Sanofi said on Friday it has decided to donate 100 million doses of hydroxychloroquine, the anti-malaria drug which could be a potential weapon against novel coronavirus, across 50 countries.

The company has already doubled its incremental production capacity on top of the usual production for current indications across its eight hydroxychloroquine manufacturing sites worldwide and is on track to quadruple it by the summer.

"In this global health emergency, Sanofi stands ready to assist as many countries as possible, starting with countries where its medicine is registered for current approved indications as well as countries where there are no hydroxychloroquine suppliers or countries with underserved populations," it said in a statement.

Sanofi called for coordination among the entire hydroxychloroquine chain worldwide to ensure the continued supply of the medicine if proven to be a well-tolerated and effective treatment in COVID-19 patients.

"The COVID-19 pandemic is an unprecedented health and economic crisis which is shaking some of the very fundamentals of international solidarity and cooperation among countries," said Chief Executive Officer Paul Hudson. "This virus does not care about the concept of borders, so we should not either," he added.

"It is critical that international authorities, local governments, manufacturers and all other players involved in the hydroxychloroquine chain work together in a coordinated manner to ensure all patients who may benefit from this potential treatment can access it. If the trials prove positive, we hope our donation will play a critical role for patients," said Hudson.

While hydroxychloroquine is generating a lot of hope for patients around the world, said Sanofi, it should be remembered that there are no results from ongoing studies and the results may be positive or negative.

To date, there is insufficient clinical evidence to draw any conclusion over the safety and efficacy of hydroxychloroquine in the management of COVID-19 patients.

It is one of several medicines being investigated by the World Health Organisation (WHO) in its international clinical trial seeking a treatment solution for COVID-19. "Sanofi is supporting ongoing trials by providing the medicine to some participating investigator sites and other independent research centres," it said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 19,2020

Washington, Apr 19: President Donald Trump has expressed his doubts over the official Chinese figures on the number of deaths in their country due to the novel coronavirus pandemic, claiming that the fatalities were way ahead of the US.

Trump's comments come two days after another 1,300 fatalities were added to the official count in the city of Wuhan, where the outbreak started. The revision puts China's overall death toll to more than 4,600.

"We are not number one; China is number one just so you understand," Trump told reporters at a White House news conference on Saturday. "They are way ahead of us in terms of death. It's not even close."

According to Trump, when highly-developed healthcare systems of the UK, France, Belgium, Italy and Spain had high fatality rates, it was O.33 in China.

The president asserted that the actual number was much more than the official Chinese death toll figures, which he said were "unrealistic".

"You know it, I know it and they know it, but you don't want to report it. Why?" he asked. "You will have to explain that. Someday I will explain it."

He also highlighted that on a per-capita basis, the mortality rate in the US was far lower than other nations of Western Europe.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 4,2020

Tokyo, Mar 4: Takeda Pharmaceutical Co said on Wednesday it was developing a drug to treat COVID-19, the flu-like illness that has struck more than 90,000 people worldwide and killed over 3,000.

The Japanese drugmaker is working on a plasma-derived therapy to treat high-risk individuals infected with the new coronavirus and will share its plans with members of the U.S. Congress on Wednesday, it said in a statement.

Takeda is also studying whether its currently marketed and pipeline products may be effective treatments for infected patients.

"We will do all that we can to address the novel coronavirus threat...(and) are hopeful that we can expand the treatment options," Rajeev Venkayya, president of Takeda's vaccine business, said in the statement.

Takeda said it was in talks with various health and regulatory agencies and healthcare partners in the United States, Asia and Europe to move forward its research into the drug.

Its research requires access to the blood of people who have recovered from the respiratory disease or who have been vaccinated, once a vaccine is developed, Takeda said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.